Wedbush initiated coverage of Opus Genetics (IRD) with an Outperform rating and $8 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics’ New Study on Vision Improvement: What Investors Need to Know
- Opus Genetics Advances Genetic Therapy for Rare Eye Conditions
- Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update
- Opus Genetics: Promising Gene Therapy Developments and Strategic Advancements Drive Buy Rating
- Opus Genetics initiated with a Buy at Chardan